Aarsland, D. et al. ANAVEX®2-73 (blarcamesine) Currently in Phase 2b/3 Early Alzheimer’s Disease (AD): Analysis of Cognitive Outcome Measures Relevant in AD of Double-blind, Multicenter, Placebo-controlled Phase 2 Clinical Trial in 132 Patients with Parkinson’s Disease Demen. Clin. Trials Alzheimer’s Dis. Conf. 2017 2020 7, S54 (2020).